Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system

作者：Hsu Fei Ting; Liu Hua Shan; Ali Ahmed Atef Ahmed; Tsai Ping Huei; Kao Yu Chieh; Lu Chia Feng; Huang Hsu Shan; Chen Cheng Yu^*

来源：Nanomedicine: Nanotechnology, Biology and Medicine , 2018, 14(3): 1019-1031.

DOI：10.1016/j.nano.2018.01.010

• Erlotinib
• Superparamagnetic iron oxide
• Magnetic resonance imaging
• Nuclear factor-kappa B
• Non-small-cell lung cancer

Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used as the first-line treatment for advanced NSCLC; however, the efficacy of drug delivery remains unknown. Hence, we successfully developed erlotinib-conjugated iron oxide nanoparticles (FeDC-E NPs) as theranostic probe that can potentially provide a new avenue for monitoring drug delivering through noninvasive magnetic resonance imaging. MRI Delta R2* relaxivity measurements offer an opportunity to quantitatively evaluate the uptake of FeDC-E NPs at cellular and tumoral levels. Additionally, NF-kappa B reporter gene system provides NF-kappa B activation status monitoring to validate the therapeutic efficiency of FeDC-E NPs. FeDC-E NPs not only inhibit the tumor growth and NF-kappa B-modulated antiapoptotic mechanism but also trigger extrinsic and intrinsic apoptotic pathways. Taken together, dual functional FeDC-E NPs offer diagnostic and therapeutic benefits against lung cancers, indicating that our presented probe could be applied in clinical.

• 出版日期2018-4